ORBIMED ADVISORS LLC - 15 Jul 2024 Form 4 Insider Report for Terns Pharmaceuticals, Inc. (TERN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Jul 2024, 20:48:54 UTC
Prior SEC filing
02 Jul 2024
Next SEC filing
15 Aug 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Terns Pharmaceuticals, Inc. (TERN) on 17 Jul 2024.

Key facts

  • This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Terns Pharmaceuticals, Inc. (TERN).
  • 6 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 17 Jul 2024, 20:48.

Change

  • Previous filing in this sequence was filed on 02 Jul 2024.
  • Current net transaction value: -$561,640.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TERN transaction

Common Stock

Sale

Transaction value
$394,330
Shares
-39,433
Change %
-0.81%
Price
$10.00
Shares after
4,843,421
Date
15 Jul 2024
Ownership
See footnotes
Footnotes
F1, F4
TERN transaction

Common Stock

Sale

Transaction value
$54,010
Shares
-5,401
Change %
-0.27%
Price
$10.00
Shares after
1,968,480
Date
15 Jul 2024
Ownership
See footnotes
Footnotes
F2, F4
TERN transaction

Common Stock

Sale

Transaction value
$61,420
Shares
-6,142
Change %
-0.81%
Price
$10.00
Shares after
756,258
Date
15 Jul 2024
Ownership
See footnotes
Footnotes
F3, F4
TERN transaction

Common Stock

Sale

Transaction value
$40,090
Shares
-4,009
Change %
-0.08%
Price
$10.00
Shares after
4,839,412
Date
16 Jul 2024
Ownership
See footnotes
Footnotes
F1, F4
TERN transaction

Common Stock

Sale

Transaction value
$5,560
Shares
-556
Change %
-0.03%
Price
$10.00
Shares after
1,967,924
Date
16 Jul 2024
Ownership
See footnotes
Footnotes
F2, F4
TERN transaction

Common Stock

Sale

Transaction value
$6,230
Shares
-623
Change %
-0.08%
Price
$10.00
Shares after
755,635
Date
16 Jul 2024
Ownership
See footnotes
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.

Footnote F2

These securities are held of record by OrbiMed Asia Partners III, L.P. ("OAP III"). OrbiMed Asia GP III, L.P. ("Asia GP") is the general partner of OAP III and OrbiMed Advisors III Limited ("Advisors III") is the general partner of Asia GP. OrbiMed Advisors is the advisory company of OAP III. By virtue of such relationships, Asia GP, Advisors III, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP III and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP III.

Footnote F3

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.

Footnote F4

This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, Genesis GP, Advisors III, and Asia GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .